Tumor-infiltrating lymphocyte scoring improves progression risk prediction in stage II melanoma: A retrospective cohort study
Stage II melanoma progression is poorly predicted by the American Joint Committee on Cancer eighth edition substage. TIL scoring offers improved risk stratification across substages and could serve as a cost-effective method to better identify patients who may benefit from adjuvant immunotherapies.
Authors
- George Adigbli (ORCID: https://orcid.org/0000-0003-3790-927X)
- Oliver Cassell
- Olivia Espinosa
- Eleni Ieremia
- Mahaveer S. Sangha (ORCID: https://orcid.org/0000-0002-8839-4811)
- Milosz Wojtowicz
- Fadi Issa (ORCID: https://orcid.org/0000-0002-8279-7732)
- Bhavika Khera
- Simran Thadani
- Jonathan Dunne (ORCID: https://orcid.org/0000-0003-0227-7866)
- Annelies Wilder‐Smith (ORCID: https://orcid.org/0000-0003-0362-5375)
- Benedict Reed (ORCID: https://orcid.org/0000-0001-9686-4951)
- Ameer Mustafa
- Mary Pissaridou
Institutions
- Buckinghamshire Healthcare NHS Trust (GB)
- Stoke Mandeville Hospital (GB)
- John Radcliffe Hospital (GB)
- University of Oxford (GB)
Publication Details
- Journal
- Journal of the American Academy of Dermatology
- Published
- 2025-03-22
- DOI
- https://doi.org/10.1016/j.jaad.2025.03.046
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute for Health and Care Research